TSRL, Inc. Awarded Two NIH Grants to Develop Therapeutics for Multi-Drug Resistant Infections

TSRL, Inc. Awarded Two NIH Grants to Develop Therapeutics for Multi-Drug Resistant Infections

ANN ARBOR, MICHIGAN, August 10th, 2017—TSRL, Inc., a privately-held preclinical accelerator, announced today that the company was awarded a Phase I Small Business Technology Transfer (STTR) grant and a Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy & Infectious Diseases (NIAID) of the National Institute of Health (NIH). TSRL and its collaborators from Purdue University and the University of Washington were awarded $3.6 million over the next three years to develop a portfolio of novel antibacterials for difficult-to-treat infections.

Read More

TSRL, Inc. Awarded NIH Grant to Develop Microneedle Patch for Treatment of Influenza

TSRL, Inc. Awarded NIH Grant to Develop Microneedle Patch for Treatment of Influenza

ANN ARBOR, MICHIGAN, February 17, 2017—TSRL, Inc., announced today that the company was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy & Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). TSRL will receive approximately $600,000 over the next two years for the development of a transdermal delivery system of zanamivir (GSK, Relenza®), an inhalation drug product used in the treatment of influenza A & B. This grant, awarded in collaboration with Dr. Audra Stinchcomb’s team at F6 Pharma, explores microneedle delivery strategies of formulations that optimize solubility and absorption of zanamivir through the skin. In addition, TSRL will be accessing NIAID’s preclinical services for pharmacology testing of the transdermal formulation.

Read More

TSRL, Inc. Client Company Acquired by Allergan

TSRL, Inc. Client Company Acquired by Allergan

Sept. 26th, 2016, Ann Arbor, Michigan: RetroSense Therapeutics, a privately-held biotechnology company developing novel gene therapies for vision restoration, announced that Allergan plc has acquired all assets related to its lead development program in an all-cash transaction. RetroSense’s RST-001 program employs a photosensitivity gene to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration. Neither of these conditions have FDA-approved treatments to improve or restore vision.

Read More